UnitedHealth Group Incorporated

Guidance / forecasts (2026 → 2027) - Revised full-year 2026 outlook: Adjusted EPS guidance raised to at least $20.50, reflecting Q3 performance plus planned investments in the final months of 2026. - 2027 growth stance: Management reiterated confidence in sustainably growing in 2027 and beyond within the 13%–16% long-term target growth range, and noted analyst consensus for 2027 may understate opportunity; they implied the lower end of 13%–16% is a more realistic starting point. - Capex/strategy investment: Continued emphasis on reinvestment in care delivery, modernization, and AI adoption, while maintaining balance sheet strength.

Financial + capital return (dividends, buybacks, balance sheet) - Q3 2026 reported results: Revenue $113B; Adjusted EPS $4.69 vs $2.92 a year ago; Medical care ratio (MCR) 88.4% vs 89.9% last year (improved). - Capital deployment: $5B share repurchases through Q3; $6.2B dividends paid YTD with expectation to exceed $8B by year-end. - Leverage: Debt-to-cap 41.7% at quarter end, on track to approach ~40% by year-end—supporting flexibility for buybacks/dividends.

Medicare Advantage outlook: strong positioning but cost/trend pressure remains - AEP (Medicare Advantage) near-term: Enrollment starting later this week; management expects MA to remain >50% of eligible seniors’ choice and highlighted perceived savings vs fee-for-service (>$4,000 annually average savings cited). - Margin expectation (important investor datapoint): 2026 MA margins expected near the top end of a 2%–4% range (attributed to recovery actions, medical trend/cost management, and durable product design). - Quality/Stars progress: Initial Star ratings for payment year 2028 reflect investments; expectation to approach ~75% of members in 4+ Star plans vs industry average ~70%. - Trend/cost challenge: Elevated utilization remains, especially late-year; they are not assuming sudden deceleration to historical patterns and are maintaining a cautious stance on clinician pricing pressure.